Remidio Innovative Solutions, a global leader in AI-powered ophthalmic diagnostics, has announced a strategic partnership with RetinaRisk, an Iceland-based health tech company, to strengthen risk-based diabetic retinopathy (DR) screening in both India and Iceland.
This alliance brings together cutting-edge technologies that combine real-time AI-driven detection with personalized risk prediction—aiming to make DR screening more accessible, accurate, and cost-effective.
Combining Detection and Prediction at the Point of Care
At the heart of the partnership are two key innovations: Remidio’s Medios DR AI, an edge-based, smartphone-integrated AI solution that detects DR in real time—without requiring internet or cloud access; and RetinaRisk’s risk prediction algorithm, which calculates a patient’s likelihood of progressing to sight-threatening DR based on clinical data such as HbA1c, blood pressure, diabetes duration, and existing DR status.
Together, these tools allow healthcare providers to triage patients based on their individual risk, extend screening intervals for low-risk individuals, and prioritize timely follow-up for high-risk patients—optimizing both outcomes and resources.
Enabling Preventive, Scalable Public Health Solutions
“This collaboration moves us beyond detection into prediction, enabling care pathways that are not just reactive but truly preventive,” said Dr. Anand Sivaraman, CEO of Remidio. “It aligns perfectly with our mission to eliminate preventable blindness using clinically robust, scalable, and accessible technologies.”
From a public health standpoint, this partnership offers a sustainable way to conduct personalized DR screening—reducing unnecessary screenings while ensuring critical cases are not missed.
Clinical Validation Supports Impact and Cost Savings
Dr. Rajiv Raman, Senior Consultant at Sankara Nethralaya, highlighted findings from a validation study using data from the SNDREAMS cohort. Conducted over four years, the study evaluated the RetinaRisk algorithm’s predictive power for sight-threatening DR in nearly 1,000 individuals with type 2 diabetes.
Adding local clinical factors such as albuminuria and baseline DR severity enabled the model to achieve an AUC of 0.853. More importantly, the personalized approach reduced screening frequency by 56% and generated annual cost savings of over 50% for patients without DR, and 41% for those with NPDR.
“Remidio’s portable fundus imaging and on-device AI grading make this a uniquely scalable, point-of-care solution. The combined platform has the potential to transform public eye health in India and beyond,” said Dr. Raman.
Proven Deployment in Iceland and Global Markets
Aegir Thor Steinarsson, CEO of RetinaRisk, noted that healthcare providers in Iceland are already using Remidio’s Fundus on Phone (FOP) and Medios DR AI effectively for national DR screening. “By combining our predictive algorithm with real-time retinal grading through a smartphone-based device, we’re offering a game-changing solution,” he said. “Together, we’re showing that AI-powered screening can be both personalized and widely accessible—in both emerging and advanced healthcare settings.”
Tackling a Growing Global Health Crisis
This collaboration comes at a critical time. Globally, over 22.27% of people with diabetes have diabetic retinopathy, and this number is expected to rise to 160.50 million by 2045. India alone accounts for more than 9.2 million cases, underlining the need for scalable, personalized screening models.
As per the press release, the Remidio and RetinaRisk partnership will begin with pilot programs in India. These will focus on high-prevalence diabetic populations. These pilots aim to build a robust framework for longitudinal patient tracking, prioritized referrals, and reduced vision loss.
Remidio’s Proven Track Record in AI-Driven Eye Care
Remidio leads in AI-enabled eye screening. It has deployed clinically validated, portable imaging devices and AI algorithms across national screening programs, vision centers, and remote clinics. So far, its technologies have enabled over 15 million screenings across more than 40 countries. They are especially impactful in low-resource environments where early detection is crucial.
With this partnership, Remidio and RetinaRisk are setting a new benchmark in risk-based, AI-enabled diabetic eye care. This collaboration paves the way for smarter and more inclusive healthcare systems.